Omeros (NASDAQ:OMER) Shares Gap Up on Earnings Beat

Omeros Corporation (NASDAQ:OMER) shares gapped up before the market opened on Wednesday after the company announced better than expected quarterly earnings. The stock had previously closed at $10.56, but opened at $11.32. Omeros shares last traded at $12.1660, with a volume of 1,088,476 shares changing hands.

The biopharmaceutical company reported $3.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $3.69.

Key Omeros News

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Q4 results beat expectations driven by a one‑time Novo Nordisk deal that materially lifted EPS; investors have been upbeat about the earnings surprise and the deal’s cash impact. Omeros Corporation Q4 2025 Earnings Call Summary
• Positive Sentiment: Management says YARTEMLEA is expected to be financially self‑sustaining in 2026 and the company is targeting positive cash flow in 2027 — a clear longer‑term de‑risking catalyst if execution continues. Omeros expects YARTEMLEA to be financially self-sustaining in 2026…
• Positive Sentiment: Unusually large call‑option buying was reported ahead of and around the earnings period, suggesting some traders expect further upside or continued volatility. (Market options flow reported 7,487 calls bought vs a typical ~4,876.)
• Neutral Sentiment: Full earnings‑call transcripts and summaries provide operational context (deal terms, launch timelines, FDA updates) but contain mixed detail; these are useful for assessing whether recent gains are sustainable. Earnings Call Transcript
• Neutral Sentiment: Analyst pieces and bullish case writeups frame a potential upside ahead of Q1 commercial updates, but they also note execution and commercialization milestones that must be met. Making The Bull Case On Q4 Earnings
• Negative Sentiment: Some analyst commentary was mixed, highlighting that the EPS beat was boosted by a one‑time windfall and that forward commercial execution and sustainable revenue proof points will determine longer‑term valuation — potentially tempering enthusiasm. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: After a post‑earnings after‑hours pop tied to the Novo deal and launch optimism, some investors appear to be taking profits or reassessing valuation, which likely contributed to intraday selling pressure. OMER stock surges 5% after-hours

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on OMER shares. D. Boral Capital reiterated a “buy” rating and issued a $36.00 target price on shares of Omeros in a research note on Tuesday, January 27th. Wall Street Zen lowered Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. HC Wainwright raised their price objective on Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Omeros has an average rating of “Moderate Buy” and a consensus price target of $40.33.

Insider Activity

In other news, CAO David J. Borges sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total transaction of $369,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 12.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC lifted its position in Omeros by 16.5% during the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 1,004 shares during the last quarter. State of Wyoming acquired a new stake in Omeros during the 4th quarter worth approximately $25,000. AQR Capital Management LLC boosted its stake in Omeros by 7.2% in the 4th quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock valued at $392,000 after purchasing an additional 1,532 shares during the period. ProShare Advisors LLC boosted its stake in Omeros by 12.1% in the 4th quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 1,637 shares during the period. Finally, Cerity Partners LLC grew its holdings in Omeros by 6.1% in the 4th quarter. Cerity Partners LLC now owns 30,450 shares of the biopharmaceutical company’s stock valued at $523,000 after buying an additional 1,750 shares in the last quarter. 48.79% of the stock is owned by institutional investors.

Omeros Trading Down 9.8%

The stock has a market cap of $784.80 million, a P/E ratio of -21.80 and a beta of 2.53. The firm has a 50-day simple moving average of $11.38 and a two-hundred day simple moving average of $9.78.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.